<code id='705B0A929A'></code><style id='705B0A929A'></style>
    • <acronym id='705B0A929A'></acronym>
      <center id='705B0A929A'><center id='705B0A929A'><tfoot id='705B0A929A'></tfoot></center><abbr id='705B0A929A'><dir id='705B0A929A'><tfoot id='705B0A929A'></tfoot><noframes id='705B0A929A'>

    • <optgroup id='705B0A929A'><strike id='705B0A929A'><sup id='705B0A929A'></sup></strike><code id='705B0A929A'></code></optgroup>
        1. <b id='705B0A929A'><label id='705B0A929A'><select id='705B0A929A'><dt id='705B0A929A'><span id='705B0A929A'></span></dt></select></label></b><u id='705B0A929A'></u>
          <i id='705B0A929A'><strike id='705B0A929A'><tt id='705B0A929A'><pre id='705B0A929A'></pre></tt></strike></i>

          knowledge

          knowledge

          author:leisure time    Page View:5727
          Surgeons prepare the pig kidney for transplantation
          Surgeons prepare the gene-edited pig kidney for transplantation at Massachusetts General Hospital. Massachusetts General Hospital

          In a new test of xenotransplantation, a medical team at Massachusetts General Hospital announced Thursday that, for the first time, it had transplanted a kidney from a CRISPR gene-edited pig into a living patient.

          Surgeons performed the milestone procedure over four hours on Saturday, March 16, without complications. The organ recipient, a 62-year-old man named Richard Slayman, had previously received a human kidney transplant, but it failed after about five years, requiring him to resume kidney dialysis in 2023.

          advertisement

          As of Thursday morning, Slayman, a manager with the Massachusetts Department of Transportation, was up and walking — he’s up to 20 laps a day around the ward — one of his physicians told STAT. His kidneys are performing well enough that he hasn’t received dialysis since the surgery, said Leonardo Riella, MGH’s medical director for kidney transplants. He is expected to be discharged soon.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          FDA's naming rule on biosimilars has undermined competition
          FDA's naming rule on biosimilars has undermined competition

          AdobeIrecentlytriedtoorderwhitebloodcellgrowthfactor(pegfilgrastim)biosimilarforoneofmypatients.This

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Why Novartis is changing the name of its research labs

          FionaMarshall,presidentoftheNovartisresearchhubinCambridge,Mass.,speaksThursdayduringtheSTATFutureSu